Lymphoblastoid interferon in controlled trials of chronic hepatitis B virus infection
Stephanos J. Hadziyannis – 1 May 1988 – A controlled trial of lymphoblastoid interferon versus no therapy in patients positive for HBsAg, HBeAg and DNA polymerase activity with separate randomisation for sexual preference and histology is underway. Thirty‐two patients have been followed for a minimum period of 6 months of whom 15 have been randomised to receive interferon thrice weekly for 6 months after a 5‐day induction phase.